Our Scientific Approach

Genetic information encoded in DNA is transcribed to RNA, which is then translated to protein. The interactions between microRNA (miRNA) and messenger RNA (mRNA) constitute a transient set of information that cells use to elaborately orchestrate protein expression. Dysregulation of this interaction can induce disease conditions.

The miRNA features that control several targets are appropriate for multifactorial diseases like Alzheimer’s disease. And the miRNAs don’t affect the genome thus it’s not a permanent genetic effect. Also, it has minimal risk of side effects through the miRNA’s transient nature. Furthermore, this transient RNA therapy shows less immune reaction and toxicity in comparison with gene-based therapy and protein-based therapy.

We, at BIORCHESTRA, develop RNA-based therapeutics that can remedy such dysregulation. RNA-based therapeutics can be categorized by the mechanism of action. Gene delivery, noncoding RNAs, RNA editing, and Antisense oligonucleotides (ASOs) bind to nucleic acids; aptamers target proteins; mRNAs encode proteins. We design a strategy for drug delivery of a selected RNA modality using our proprietary drug delivery system (DDS).